NEW YORK, June 13, 2014 /PRNewswire/ -- Pomerantz LLP
is investigating claims on behalf of investors of Idenix
Pharmaceuticals, Inc. ("Idenix" or the "Company") (NASDAQ: IDIX)
(ISIN: US45166R2040) (CUSIP: 45166R204) concerning the proposed
acquisition of Idenix by Merck & Co.
Idenix shareholders seeking more information about this
acquisition are advised to contact Robert
Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or
888-476-6529, ext. 237.
The investigation concerns whether the Idenix directors are
breaching their fiduciary duties by failing to adequately shop the
Company and maximize shareholder value. Under the terms
of the agreement, each share of Idenix will be exchanged for
$24.50 in cash.
Pomerantz LLP, with offices in New
York, Chicago, Florida, and San
Diego, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz LLP pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz LLP continues in the
tradition he established, fighting for the rights of the victims of
securities fraud, breaches of fiduciary duty, and corporate
misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of defrauded investors. See
www.pomerantzlaw.com.
CONTACT:
Robert
Willoughby
Pomerantz LLP
212-661-1100 ext. 237
rswilloughby@pomlaw.com
SOURCE Pomerantz LLP